A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021
AGOURA HILLS, Calif., Nov. 12, 2021 /PRNewswire/ — A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of a first-in-class Tmod™ T cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to…
Comments Off on A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021